Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight loss of up to 20% over 52 weeks in individuals living with obesity or overweight but without type 2 diabetes. For those with diabetes, the average weight loss reached 17%.
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...
Wall Street Journal on MSN4d
Amgen Obesity Drug Cut Weight In Closely Watched StudyA highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...
STORY: Shares of Amgen on Tuesday were on track for their biggest percentage fall in more than two decades after the ...
Key TakeawaysA Phase 2 study of Amgen's experimental weight-loss treatment didn't meet expectations of analysts.Concerns were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback